Dr. Barrientos on Treatment Options for Patients With TP53 Mutations or 17p Deletions in CLL
Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.
Dr. Barrientos on Selecting Between BCL-2 Inhibitors and BTK Inhibitors in CLL
Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.
Dr. Barrientos on Treatment Considerations for CLL
Jacqueline Claudia Barrientos, MD, MS, discusses treatment considerations for patients with chronic lymphocytic leukemia.
New Strategies Emerge for Managing CLL Patients in Community Settings
The treatment landscape for patients with chronic lymphocytic leukemia (CLL) is rapidly changing, with the emergence of four new therapeutic options for this malignancy in recent months.
Odronextamab Exhibits Continued Clinical Activity and Tolerable Safety Profile in R/R DLBCL
MRD-Guided Ibrutinib Plus Venetoclax Improves Survival in Treatment-Naive CLL
Retrospective Analysis Supports Utilization of Auto-HCT in Relapsed LBCL Achieving a CR
Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden
2 Clarke Drive Cranbury, NJ 08512